Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines

A study published in the New England Journal of Medicine in August 2026 examined cross-reactive antibodies against Bundibugyo in individuals who received licensed Ebola vaccines. Bundibugyo is one of the species of Ebola virus. The research found that Ebola vaccines can trigger an immune response that also reacts to other species of Ebola virus. This cross-reactivity suggests potential protection against multiple variants of Ebola virus. The results are significant for understanding the broad immune coverage of licensed vaccines. The study was published in a renowned medical journal and contributes to knowledge about the effectiveness of vaccines against different types of Ebola.